Tofacitinib for Patients with Anti-TNF Refractory Ulcerative Proctitis : A Multicentre Cohort Study from the GETAID
© The Author(s) 2023. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissionsoup.com..
BACKGROUND: Although ulcerative proctitis [UP] can dramatically impair quality of life, treatment efficacy has been poorly investigated in UP as it was historically excluded from phase 2/3 randomised controlled trials in ulcerative colitis. Our aim was to assess the effectiveness and safety of tofacitinib for the treatment of UP.
METHODS: We conducted a retrospective, multicentre study in 17 GETAID centres, including consecutive patients with UP treated with tofacitinib. The primary endpoint was steroid-free remission between Week 8 and Week 14, defined as a partial Mayo score of 2 [and no individual subscore above 1]. Secondary outcomes included clinical response and steroid-free remission after induction and at 1 year.
RESULTS: All the 35 enrolled patients previously received anti-tumour necrosis factor [TNF] therapy and 88.6% were exposed to at least two lines of biologics. At baseline, the median partial Mayo score was 7 (intequartile range [IQR] [5.5-7]). After induction [W8-W14], 42.9% and 60.0% of patients achieved steroid-free remission and clinical response, respectively. At 1 year, the steroid-free clinical remission and clinical response rates were 39.4% and 45.5%, respectively, and 51.2% [17/33] were still receiving tofacitinib treatment. Survival without tofacitinib withdrawal was estimated at 50.4% (95% confidence interval [CI] [35.5-71.6]) at 1 year. Only a lower partial Mayo at baseline was independently associated with remission at induction (0dds ratio [OR] = 0.56 for an increase of 1, (95% CI [0.33-0.95], p = 0.03). Five [14.3%] adverse events were reported, with one leading to treatment withdrawal [septic shock secondary to cholecystitis].
CONCLUSION: Tofacitinib may offer a therapeutic option for patients with refractory UP.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Journal of Crohn's & colitis - 18(2024), 3 vom: 01. März, Seite 424-430 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Uzzan, Mathieu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
87LA6FU830 |
|---|
| Anmerkungen: |
Date Completed 04.03.2024 Date Revised 04.03.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/ecco-jcc/jjad169 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36289745X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36289745X | ||
| 003 | DE-627 | ||
| 005 | 20240304231953.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ecco-jcc/jjad169 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1316.xml |
| 035 | |a (DE-627)NLM36289745X | ||
| 035 | |a (NLM)37796025 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Uzzan, Mathieu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tofacitinib for Patients with Anti-TNF Refractory Ulcerative Proctitis |b A Multicentre Cohort Study from the GETAID |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.03.2024 | ||
| 500 | |a Date Revised 04.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: Although ulcerative proctitis [UP] can dramatically impair quality of life, treatment efficacy has been poorly investigated in UP as it was historically excluded from phase 2/3 randomised controlled trials in ulcerative colitis. Our aim was to assess the effectiveness and safety of tofacitinib for the treatment of UP | ||
| 520 | |a METHODS: We conducted a retrospective, multicentre study in 17 GETAID centres, including consecutive patients with UP treated with tofacitinib. The primary endpoint was steroid-free remission between Week 8 and Week 14, defined as a partial Mayo score of 2 [and no individual subscore above 1]. Secondary outcomes included clinical response and steroid-free remission after induction and at 1 year | ||
| 520 | |a RESULTS: All the 35 enrolled patients previously received anti-tumour necrosis factor [TNF] therapy and 88.6% were exposed to at least two lines of biologics. At baseline, the median partial Mayo score was 7 (intequartile range [IQR] [5.5-7]). After induction [W8-W14], 42.9% and 60.0% of patients achieved steroid-free remission and clinical response, respectively. At 1 year, the steroid-free clinical remission and clinical response rates were 39.4% and 45.5%, respectively, and 51.2% [17/33] were still receiving tofacitinib treatment. Survival without tofacitinib withdrawal was estimated at 50.4% (95% confidence interval [CI] [35.5-71.6]) at 1 year. Only a lower partial Mayo at baseline was independently associated with remission at induction (0dds ratio [OR] = 0.56 for an increase of 1, (95% CI [0.33-0.95], p = 0.03). Five [14.3%] adverse events were reported, with one leading to treatment withdrawal [septic shock secondary to cholecystitis] | ||
| 520 | |a CONCLUSION: Tofacitinib may offer a therapeutic option for patients with refractory UP | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Ulcerative proctitis | |
| 650 | 4 | |a refractory proctitis | |
| 650 | 4 | |a tofacitinib | |
| 650 | 7 | |a tofacitinib |2 NLM | |
| 650 | 7 | |a 87LA6FU830 |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor Inhibitors |2 NLM | |
| 650 | 7 | |a Piperidines |2 NLM | |
| 650 | 7 | |a Pyrimidines |2 NLM | |
| 700 | 1 | |a Nachury, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Nuzzo, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Amiot, Aurélien |e verfasserin |4 aut | |
| 700 | 1 | |a Caron, Bénédicte |e verfasserin |4 aut | |
| 700 | 1 | |a Benezech, Alban |e verfasserin |4 aut | |
| 700 | 1 | |a Buisson, Anthony |e verfasserin |4 aut | |
| 700 | 1 | |a Bouguen, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Le Berre, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Reenaers, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Le Cosquer, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Savoye, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Charkaoui, Maeva |e verfasserin |4 aut | |
| 700 | 1 | |a Vidon, Mathias |e verfasserin |4 aut | |
| 700 | 1 | |a Guillo, Lucas |e verfasserin |4 aut | |
| 700 | 1 | |a Fumery, Mathurin |e verfasserin |4 aut | |
| 700 | 1 | |a Peyrin-Biroulet, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Kirchgesner, Julien |e verfasserin |4 aut | |
| 700 | 1 | |a Bouhnik, Yoram |e verfasserin |4 aut | |
| 700 | 0 | |a GETAID TOFA-PRO study group |e verfasserin |4 aut | |
| 700 | 1 | |a Fumery, Mathurin |e investigator |4 oth | |
| 700 | 1 | |a Yzet, Clara |e investigator |4 oth | |
| 700 | 1 | |a Brazier, Franck |e investigator |4 oth | |
| 700 | 1 | |a Billiauws, Lore |e investigator |4 oth | |
| 700 | 1 | |a Bouhnik, Yoram |e investigator |4 oth | |
| 700 | 1 | |a Nuzzo, Alexandre |e investigator |4 oth | |
| 700 | 1 | |a Amiot, Aurélien |e investigator |4 oth | |
| 700 | 1 | |a Carbonnel, Franck |e investigator |4 oth | |
| 700 | 1 | |a Bresteau, Clément |e investigator |4 oth | |
| 700 | 1 | |a Meyer, Antoine |e investigator |4 oth | |
| 700 | 1 | |a Bellanger, Christophe |e investigator |4 oth | |
| 700 | 1 | |a Nachury, Maria |e investigator |4 oth | |
| 700 | 1 | |a Wils, Pauline |e investigator |4 oth | |
| 700 | 1 | |a Desreumaux, Pierre |e investigator |4 oth | |
| 700 | 1 | |a Branche, Julien |e investigator |4 oth | |
| 700 | 1 | |a Gérard, Romain |e investigator |4 oth | |
| 700 | 1 | |a Assaraf, Julie |e investigator |4 oth | |
| 700 | 1 | |a Gagnière, Charlotte |e investigator |4 oth | |
| 700 | 1 | |a Uzzan, Mathieu |e investigator |4 oth | |
| 700 | 1 | |a Beaugerie, Laurent |e investigator |4 oth | |
| 700 | 1 | |a Sokol, Harry |e investigator |4 oth | |
| 700 | 1 | |a Seksik, Philippe |e investigator |4 oth | |
| 700 | 1 | |a Bourrier, Anne |e investigator |4 oth | |
| 700 | 1 | |a Kirchgesner, Julien |e investigator |4 oth | |
| 700 | 1 | |a McLellan, Paul |e investigator |4 oth | |
| 700 | 1 | |a Le Cosquer, Guillaume |e investigator |4 oth | |
| 700 | 1 | |a Gilletta, Cyrielle |e investigator |4 oth | |
| 700 | 1 | |a Caron, Bénédicte |e investigator |4 oth | |
| 700 | 1 | |a Peyrin-Biroulet, Laurent |e investigator |4 oth | |
| 700 | 1 | |a Guilmoteau, Thomas |e investigator |4 oth | |
| 700 | 1 | |a Dodel, Marie |e investigator |4 oth | |
| 700 | 1 | |a Coban, Dilek |e investigator |4 oth | |
| 700 | 1 | |a Bouhnik, Yoram |e investigator |4 oth | |
| 700 | 1 | |a Cohen, Mathilde |e investigator |4 oth | |
| 700 | 1 | |a Treton, Xavier |e investigator |4 oth | |
| 700 | 1 | |a Guillo, Lucas |e investigator |4 oth | |
| 700 | 1 | |a Serrero, Mélanie |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Crohn's & colitis |d 2007 |g 18(2024), 3 vom: 01. März, Seite 424-430 |w (DE-627)NLM204021901 |x 1876-4479 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2024 |g number:3 |g day:01 |g month:03 |g pages:424-430 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ecco-jcc/jjad169 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2024 |e 3 |b 01 |c 03 |h 424-430 | ||